A rboviruses, including West Nile virus (WNV), dengue virus (DENV), chikungunya virus (CHIKV), and Zika virus (ZIKV), have the potential to threaten blood transfusion safety worldwide given that presymptomatic viremia and asymptomatic infections can occur. The first case of arboviral transfusion transmission was in 2002, with WNV being the etiologic agent. 1, 2 After this, DENV and CHIKV have impacted blood transfusion safety globally [3] [4] [5] and ZIKV has recently joined this group as a potential risk to transfusion safety worldwide. ZIKV is an enveloped, single-strand RNA virus that belongs to the Flavivirus genus in the Flaviviridae family. 7 ZIKV is predominantly transmitted through an enzootic sylvatic transmission route by various Aedes spp. mosquitoes. 8 Human infection can occur, creating a human-tohuman transmission cycle through A. aegypti 9 or through nonvector routes such as sexual contact. 10, 11 Transplacental transmission has been demonstrated when infection occurs during pregnancy 12 and transfusion transmission has also been documented. [13] [14] [15] The clinical manifestations of ZIKV infection can vary from being asymptomatic, to common self-resolving symptoms including macular or maculopapular rash, arthralgia, low-grade fever, headache, myalgia, and retroorbital pain. 16 When acquired during pregnancy, transmission may result in miscarriage or congenital defects including microcephaly. 17 Outbreaks of ZIKV have resulted in an estimated 1.5 million cases between 2013 and 2015. 9, 18 Pathogen inactivation (PI) provides an approach to managing the risk of transmitting blood-borne pathogens through blood transfusion. Different techniques have been applied to successfully inactivate or remove the ability of a pathogen to replicate within a blood component or product. The THERAFLEX UV-Platelets system, designed by MacoPharma for plasma-reduced platelets (PLTs) in additive solution (PAS), utilizes ultraviolet C (UVC) light with agitation to cause cyclobutanepyrimidine and pyrimidine-pyrimidone dimers within the genome of the pathogen, thus preventing elongation of the nucleic acid transcripts. 19 For plasma components, the THERAFLEX MB-Plasma system (also designed by MacoPharma) utilizes a photosensitive agent (methylene blue [MB] ) and visible light at 630 nm to intercalate into the RNA/DNA backbone of the pathogen's genome, leading to guanosine oxidation and nucleic acid strand breakages upon excitation. 20 Both of these systems have been shown to inactivate a myriad of viruses, including arboviruses such as WNV, DENV, and CHIKV; [21] [22] [23] [24] however, the ability of each system to inactivate ZIKV remained to be determined. Therefore, this study investigated the efficacy of the THERAFLEX UV-Platelets and THERAFLEX MBPlasma systems to inactivate ZIKV spiked into plasmareduced PLTs and plasma.
MATERIALS AND METHODS

Blood components
This study had approval from the Australian Red Cross Blood Service (Blood Service) Human Research Ethics Committee. All whole blood and plasmapheresis donations were from eligible, voluntary, nonremunerated blood donors. Whole blood units were collected into top-andbottom bags containing 66.5 mL CPD (MacoPharma) to a total volume of 470 mL (645 mL). These units were then stored and processed as previously described 23, 25 to create a buffy coat-derived PLT concentrate (PC) in PAS (SSP1; MacoPharma), containing 28% residual plasma. Plasmapheresis donations were collected, stored, and made into pooled plasma aliquots as described previously. 24 Where possible, buffy coats and plasmapheresis units were selected from young blood donors (under the age of 45 years at time of donation) residing in the Brisbane area, to minimize the presence of cross-reactive antibodies from those previously exposed to DENV.
Quality assessment of PCs
Each PC was assessed for the following quality control (QC) variables: PLT count (CELL-DYN Ruby, Abbott Laboratories), pH (Seven Multi, Mettler Toledo Ltd), swirl (visual inspection), and final unit volume. The PLT unit volume was determined as described previously. 23 This volume was further adjusted to account for a net increase of 10 mL due to viral spiking (see "Viral inactivation in PLTs" section), and any additional volume removed where needed (before spiking) to meet specifications required by the THERAFLEX UV-Platelets system instructions (325-375 mL). The PLT count was also adjusted to take into account the final volume of the PC after viral spiking.
Arbovirus antibody detection in apheresis plasma
Plasmapheresis donations were tested for the presence of anti-ZIKV or anti-DENV IgM and IgG before pooling with commercially available enzyme-linked immunosorbent assays (ELISAs; human ZIKV IgM ELISA, MyBioSource; human ZIKV IgG ELISA, MyBioSource; dengue IgM capture ELISA, Alere Diagnostic Systems; dengue IgG indirect ELISA, Alere Diagnostic Systems) in accordance with the manufacturer's instructions. Any plasmapheresis donations that were negative for antibodies against ZIKV or DENV were included in this study.
Cell culture
African green monkey kidney cells (Vero; ATCC CCL-81) were cultured in Dulbecco's modified Eagle medium (DMEM; Thermofisher) with 5% heat-inactivated fetal bovine serum (FBS, Sigma-Aldrich), penicillin (50 U/mL), streptomycin (50 mg/mL), and L-glutamine (2 mmol/L; Gibco) at 378C/5% CO 2 for propagating ZIKV. For inactivation studies, cells were cultured in reduced serum medium (Opti-MEM, Thermofisher) with 3% heatinactivated FBS at 378C/5% CO 2 . Cells were trypsinized with a 0.25% trypsin-EDTA solution (Thermofisher) before reaching confluence and resuspended in new growth medium before seeding onto a new growth surface.
Viruses and viral production ZIKV MR766 strain was grown to a concentration of 10 6 to 10 8 plaque-forming units (PFU)/mL) by propagation in Vero cells at a multiplicity of infection of 0.002 in DMEM with 2% FBS. Virus culture supernatants were harvested 3 days postinfection, clarified by centrifugation, and aliquoted with additional FBS being added to give a final concentration of 10%. Supernatants were frozen at 2808C until required. The stock concentration of propagated virus was determined using a plaque assay (outlined below).
Viral inactivation in PCs
PCs were treated with the THERAFLEX UV-Platelets system (MacoPharma) in accordance with the manufacturer's instructions, as described previously, 23 but incorporating a "hold" sample as per our previous study. 24 
Viral inactivation in pooled plasma
Pooled plasma aliquots were thawed and treated with the THERAFLEX MB-Plasma system in accordance with the manufacturer's instructions, as described previously.
24
Evaluation of infectious virus
ZIKV infectivity was determined using a modified version of the conventional plaque assay, as described previously, 23, 24 with the following viral-specific conditions.
Incubation with medium 199-3% carboxymethyl-cellulose (Sigma-Aldrich)/3% heat-inactivated FBS was for 2 days at 378C/5% CO 2 . The primary antibody was an anti-flavivirus 4G2 antibody (1:100) and the secondary antibody was IRDye800-rabbit anti-mouse (1:5000, Rockland).
RESULTS
Before treatment all PCs showed an acceptable positive "swirl" and pH, and each PC had a PLT count and final volume that met specifications for inactivation on the THERAFLEX UV-Platelets system (PLT count, 0.8 3 10 9 -1.4 3 10 9 /mL; PLT unit volume, 325-375 mL; data not shown). Plasmapheresis donations used to create the pooled plasma units contained no IgM or IgG antibodies against DENV or ZIKV (data not shown).
The efficacy of the THERAFLEX UV-Platelets system to inactivate ZIKV in PCs was investigated at a range of UVC doses, including the standard dose of 0.20 J/cm 2 . Treatment with this system resulted in the reduction of ZIKV by a mean of at least 3.80 log and 5.00 log as assessed via the large-volume plating plaque assay ( Table  1) . Detection of residual virus reached the detection limit of the plaque assay at 0.15 J/cm 2 and at the standard UVC dose for the large-volume plating plaque assay. As expected, dose dependency was observed with increasing UVC dose (Table 1) . Minimal inactivation of ZIKV was observed in the hold sample ( Table 1) . The efficacy of the THERAFLEX MB-Plasma system to inactivate ZIKV in plasma was also investigated, but at a range of visible light doses, including the standard illumination dose of 120 J/cm 2 . The THERAFLEX MBPlasma system reduced ZIKV by a mean of at least 4.48 log and at least 5.68 log as assessed via the large-volume plating plaque assay (Table 2) . Residual viral infectivity fell below the detection limit of the assays used at 20 and at 40 J/cm 2 for the large-volume plating plaque assay (Table 2 ). Viral infectivity was reduced minimally in the hold sample (0.58 log; Table 2 ).
DISCUSSION
ZIKV has emerged as a public health and transfusion safety concern worldwide. PI presents an alternate yet proactive approach to manage the risk of transmitting blood-borne pathogens through blood transfusions. The THERAFLEX UV-Platelets system and the THERAFLEX MB-Plasma system have been designed to reduce the ability of a pathogen to replicate, as demonstrated for a number of different agents. [19] [20] [21] [22] [23] [24] In this study we show that ZIKV can be effectively inactivated by the THERAFLEX UV-Platelets system and THERAFLEX MB-Plasma system. The residual infectivity of ZIKV in PCs was reduced by a mean of 5.00 log at the highest UVC dose studied, which is the standard dose used on the THERAFLEX UV-Platelets system (0.20 J/cm 2 ). At this dose, the residual viral infectivity was at the detection limit of the assays used. These results are similar to other arboviruses treated with this system, such as DENV-1 to -4 (4.59 log), Ross River virus (>5.13 log), and CHIKV (6.34 log) 23 and for other bloodborne viruses such as vesicular stomatitis virus, porcine parvovirus, encephalomyocarditis virus (hepatitis A virus model), and hepatitis C virus. 19, 22, 26 WNV was reduced by 3.5 to 4.0 log at the standard UVC dose; 22 the differences in the levels of reduction of WNV and ZIKV may be due to differences in the methods used. As expected, dose dependency was observed with increasing UVC dose, which is comparable to what has been observed for WNV, 22 DENV, Ross River virus, and CHIKV. 23 For ZIKV spiked into pooled plasma, the residual infectivity fell below the detection limit of the large-volume plating plaque assay at a visible light dose of 40 J/cm 2 , which is one-third of the standard dose emitted by the MacoTronic B2 illuminator. The resulting mean level of reduction at this dose was at least 5.68 log, which is consistent with that for DENV-1 to -3 (>5.17 log) and CHIKV ( 6.58 log) treated with the same PI system. 24 Studies with WNV were conducted using an older illumination system, the MacoTronic V4 (MacoPharma), which uses sodium vapor lamps at a wavelength of 590 nm and a dose of 180 J/cm 2 , which is comparable with the dose of 120 J/cm 2 delivered by the MacoTronic B2 device that uses LEDS at 630 nm. 27 The level of inactivation achieved reached the detection limit of the assays used at 100 J/cm 2 of visible light illumination. 21 This study has shown the THERAFLEX UV-Platelets system and THERAFLEX MB-Plasma system can effectively reduce ZIKV infectivity to the limit of detection of the assays used in PCs and pooled plasma, respectively. Inactivation of ZIKV with the INTERCEPT PI system in PLTs suspended in 35 or 100% plasma resulted in more than 4.1 log reduction in viral infectivity, 28 whereas for plasma, more than 6.46 log reduction was achieved. 29 Laughhunn and colleagues 30 have also shown the capacity of a novel inactivation process to reduce ZIKV infectivity in red blood cells (RBCs) by more than 4.3 log, whereby components are treated with amustaline (S-303) and glutathione without the need for illumination. Variable viral loads have been detected in ZIKV-infected blood donors, 29 and not all recipients of ZIKV-infected blood develop symptoms indicative of disease after transfusion. 13, 14, 31 It is clear that additional studies are urgently needed. Studies are also required to understand the threshold concentration that could elicit infection in a transfusion recipient, which is essential for assessing the suitability of any PI system to effectively manage the risk of transfusion transmission. While PI may effectively reduce the infectivity of some pathogens in PCs and plasma, it is not without inherent drawbacks, which are common to all technology variants and have been covered in detail in previous studies. 32 Specifically related to the systems used in this study, increased metabolism and surface expression of CD62P and phosphatidylserine have been observed in PLTs after treatment with UVC, [33] [34] [35] [36] while a reduction in coagulation Factors II, V, VIII, IX, X, and XII as well as fibrinogen has been observed in treated plasma. [37] [38] [39] [40] Whereas the MB/ light method is, due to its toxicity for cells, only applicable to plasma, there is proof-of-principle for the UVC technology that it could also be used to treat RBC units (A. Seltsam, personal communication, June 2017). With ZIKV being transmissible through nonvector routes and continuing to spread throughout the Americas, new strategies are required to minimize the risk of transfusion transmission. Provided that PI has been shown to effectively inactivate ZIKV it may prove to be a suitable option to manage the transfusion transmission risk. This study has shown that the THERAFLEX UV-Platelets system and THERAFLEX MB-Plasma system can effectively inactivate ZIKV in PCs and pooled plasma, thus increasing the number of viruses inactivated by these systems.
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